Array BioPharma, Inc.
3200 Walnut Street
Boulder
Colorado
80301
United States
Tel: 303-381-6600
Fax: 303-381-6697
Website: http://www.arraybiopharma.com/
Email: bd@arraybiopharma.com
467 articles about Array BioPharma, Inc.
-
Pfizer Completes Acquisition of Array Biopharma
7/30/2019
Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
-
Array BioPharma Inc., a Subsidiary of Pfizer Inc., Announces Effective Date of Make-Whole Fundamental Change and Fundamental Change Company Notice Relating to its 2.625% Convertible Senior Notes due 2024
7/30/2019
Array BioPharma Inc. ("Array") today announced that, in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2019, by and among Array, Pfizer Inc., a Delaware corporation ("Pfizer"), and Arlington Acquisition Sub Inc., a Delaware corporation and a wholly owned subsidiary of Pfizer,
-
Clinical Catch-Up for July 8-12
7/15/2019
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look. -
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
-
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
7/6/2019
Array BioPharma Inc. announced the presentation of results from the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor, and ERBITUX® (cetuximab), an anti-EGFR antibody (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy.
-
Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
6/25/2019
Array BioPharma Inc. announced that it will present updated data from the combination of BRAFTOVI®, a BRAF inhibitor, MEKTOVI®, a MEK inhibitor, and ERBITUX®, an anti-EGFR antibody, in patients with advanced BRAFV600E-mutant metastatic colorectal cancer, following one or two lines of therapy.
-
SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition
6/18/2019
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma in connection with the proposed acquisition of the Company by Pfizer Inc..
-
Pfizer to Acquire Array BioPharma
6/17/2019
Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term
-
Pfizer to Acquire Array BioPharma - June 17, 2019
6/17/2019
Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term
-
Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
6/4/2019
Array BioPharma Inc. announced that its Chief Operating Officer, Andrew Robbins, will speak at the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, California.
-
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
5/29/2019
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2019 Global Healthcare Conference in New York City.
-
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
5/29/2019
Array BioPharma Inc. (Nasdaq: ARRY) announced that that it will present data from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant melanoma in an oral poster discussion on June 3, 2019, at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
-
Here’s a roundup of some of the top clinical trial news from the previous week.
-
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
5/21/2019
Array BioPharma Inc. announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI®, a BRAF inhibitor, MEKTOVI®, a MEK inhibitor, and ERBITUX®, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer, following one or two prior lines of therapy.
-
Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
5/9/2019
Array BioPharma Inc. announced that its Chief Executive Officer, Ron Squarer, will speak at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas.
-
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
5/7/2019
Array BioPharma Inc. reported results for its third quarter of fiscal 2019 and provided an update on the progress of its key commercial products and clinical development programs.
-
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019
4/30/2019
Array BioPharma Inc. will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, May 7, 2019 at 9:00 am ET.
-
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the NCCN Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal
3/18/2019
Array BioPharma Inc. announced that the National Comprehensive Cancer Network® has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI® in combination with MEKTOVI® and an anti-EGFR antibody as a Category 2a treatment for patients with BRAFV600E-mutant metastatic colorectal cancer, after failure of one or two prior lines of therapy for metastatic disease.
-
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
3/5/2019
Array BioPharma Inc. announced that its Chief Executive Officer, Ron Squarer, will speak at the 39th Annual Cowen Health Care Conference in Boston.
-
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
2/21/2019
Array BioPharma Inc. announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8th Annual Global Healthcare Conference in New York.